The Preferred Reporting Items for Systematic Review and Meta-Analysis of Diagnostic Test Accuracy studies (PRISMA-DTA): Explanation, Elaboration and Checklist

Jean-Paul Salameh; Patrick N M Bossuyt; Trevor A McGrath; Brett D Thombs; Christopher J Hyde; Petra Macaskill; Jonathan J Deeks; Mariska Leeflang; Daniël A Korevaar; Penny F Whiting; Yemisi Takwoingi; Johannes B Reitsma; Jérémie F Cohen; Robert Frank; Harriet A Hunt; Lotty Hooft; Anne W S Rutjes; Brian H Willis; Constantine Gatsonis; Brook Levis; David Moher; Matthew D F McInnes

doi:10.1136/bmj.m2632

The Preferred Reporting Items for Systematic Review and Meta-Analysis of Diagnostic Test Accuracy studies (PRISMA-DTA): Explanation, Elaboration and Checklist

Jean-Paul Salameh, Patrick N M Bossuyt, Trevor A McGrath, Brett D Thombs, Christopher J Hyde, Petra Macaskill, Jonathan J Deeks, Mariska Leeflang, Daniël A Korevaar, Penny F Whiting, Yemisi Takwoingi, Johannes B Reitsma, Jérémie F Cohen, Robert Frank, Harriet A Hunt, Lotty Hooft, Anne W S Rutjes, Brian H Willis, Constantine Gatsonis, Brook LevisDavid Moher, Matthew D F McInnes^*

^*Corresponding author for this work

Research output: Contribution to journal › Article (Academic Journal) › peer-review

379 Citations (Scopus)

498 Downloads (Pure)

Abstract

Systematic reviews of diagnostic test accuracy (DTA) studies are fundamental to the decision-making process in evidence-based medicine. Although such studies are regarded as high-level evidence, these reviews are not always reported completely and transparently. Sub-optimal reporting of DTA systematic reviews compromises their validity and generalizability, and subsequently their value to key stakeholders. PRISMA-DTA, an extension of the PRISMA statement, was recently developed to improve the quality of reporting of DTA systematic reviews. The PRISMA-DTA statement consists of 27 items, of which 8 are unmodified from the original PRISMA statement. This document provides an explanation for the 19 new and modified items, along with their meaning and rationale. Examples of complete reporting are used for each item to illustrate best practices. The PRISMA-DTA statement, this explanation and elaboration document, and the associated web site (http://www.prisma-statement.org/Extensions/DTA) provide resources to support the complete and transparent reporting of DTA systematic reviews.

Original language	English
Article number	m2632
Journal	BMJ
Volume	370
DOIs	https://doi.org/10.1136/bmj.m2632
Publication status	Accepted/In press - 20 May 2020

Access to Document

10.1136/bmj.m2632

Full-text PDF (final published version)
This is the final published version of the article (version of record). It first appeared online via BMJ at https://www.bmj.com/content/370/bmj.m2632. Please refer to any applicable terms of use of the publisher.
Final published version, 280 KB

Handle.net

Persistent link

Embargoed Document

Full-text PDF (author accepted manuscript)
Accepted author manuscript, 1.12 MB
Request copy

Professor Penny F Whiting
- Penny.Whitingbristol.acuk
- Bristol Medical School (PHS) - Professor of Clinical Epidemiology
- Bristol Population Health Science Institute
Person: Academic , Member

Cite this

Salameh, J.-P., Bossuyt, P. N. M., McGrath, T. A., Thombs, B. D., Hyde, C. J., Macaskill, P., Deeks, J. J., Leeflang, M., Korevaar, D. A., Whiting, P. F., Takwoingi, Y., Reitsma, J. B., Cohen, J. F., Frank, R., Hunt, H. A., Hooft, L., Rutjes, A. W. S., Willis, B. H., Gatsonis, C., ... McInnes, M. D. F. (Accepted/In press). The Preferred Reporting Items for Systematic Review and Meta-Analysis of Diagnostic Test Accuracy studies (PRISMA-DTA): Explanation, Elaboration and Checklist. BMJ, 370, Article m2632. https://doi.org/10.1136/bmj.m2632

@article{5d967bb06dc549969e68c5d44736dd32,

title = "The Preferred Reporting Items for Systematic Review and Meta-Analysis of Diagnostic Test Accuracy studies (PRISMA-DTA): Explanation, Elaboration and Checklist",

abstract = "Systematic reviews of diagnostic test accuracy (DTA) studies are fundamental to the decision-making process in evidence-based medicine. Although such studies are regarded as high-level evidence, these reviews are not always reported completely and transparently. Sub-optimal reporting of DTA systematic reviews compromises their validity and generalizability, and subsequently their value to key stakeholders. PRISMA-DTA, an extension of the PRISMA statement, was recently developed to improve the quality of reporting of DTA systematic reviews. The PRISMA-DTA statement consists of 27 items, of which 8 are unmodified from the original PRISMA statement. This document provides an explanation for the 19 new and modified items, along with their meaning and rationale. Examples of complete reporting are used for each item to illustrate best practices. The PRISMA-DTA statement, this explanation and elaboration document, and the associated web site (http://www.prisma-statement.org/Extensions/DTA) provide resources to support the complete and transparent reporting of DTA systematic reviews.",

author = "Jean-Paul Salameh and Bossuyt, {Patrick N M} and McGrath, {Trevor A} and Thombs, {Brett D} and Hyde, {Christopher J} and Petra Macaskill and Deeks, {Jonathan J} and Mariska Leeflang and Korevaar, {Dani{\"e}l A} and Whiting, {Penny F} and Yemisi Takwoingi and Reitsma, {Johannes B} and Cohen, {J{\'e}r{\'e}mie F} and Robert Frank and Hunt, {Harriet A} and Lotty Hooft and Rutjes, {Anne W S} and Willis, {Brian H} and Constantine Gatsonis and Brook Levis and David Moher and McInnes, {Matthew D F}",

year = "2020",

month = may,

day = "20",

doi = "10.1136/bmj.m2632",

language = "English",

volume = "370",

journal = "BMJ",

issn = "0959-8138",

publisher = "BMJ Publishing Group",

}

Salameh, J-P, Bossuyt, PNM, McGrath, TA, Thombs, BD, Hyde, CJ, Macaskill, P, Deeks, JJ, Leeflang, M, Korevaar, DA, Whiting, PF, Takwoingi, Y, Reitsma, JB, Cohen, JF, Frank, R, Hunt, HA, Hooft, L, Rutjes, AWS, Willis, BH, Gatsonis, C, Levis, B, Moher, D & McInnes, MDF 2020, 'The Preferred Reporting Items for Systematic Review and Meta-Analysis of Diagnostic Test Accuracy studies (PRISMA-DTA): Explanation, Elaboration and Checklist', BMJ, vol. 370, m2632. https://doi.org/10.1136/bmj.m2632

TY - JOUR

T1 - The Preferred Reporting Items for Systematic Review and Meta-Analysis of Diagnostic Test Accuracy studies (PRISMA-DTA)

T2 - Explanation, Elaboration and Checklist

AU - Salameh, Jean-Paul

AU - Bossuyt, Patrick N M

AU - McGrath, Trevor A

AU - Thombs, Brett D

AU - Hyde, Christopher J

AU - Macaskill, Petra

AU - Deeks, Jonathan J

AU - Leeflang, Mariska

AU - Korevaar, Daniël A

AU - Whiting, Penny F

AU - Takwoingi, Yemisi

AU - Reitsma, Johannes B

AU - Cohen, Jérémie F

AU - Frank, Robert

AU - Hunt, Harriet A

AU - Hooft, Lotty

AU - Rutjes, Anne W S

AU - Willis, Brian H

AU - Gatsonis, Constantine

AU - Levis, Brook

AU - Moher, David

AU - McInnes, Matthew D F

PY - 2020/5/20

Y1 - 2020/5/20

N2 - Systematic reviews of diagnostic test accuracy (DTA) studies are fundamental to the decision-making process in evidence-based medicine. Although such studies are regarded as high-level evidence, these reviews are not always reported completely and transparently. Sub-optimal reporting of DTA systematic reviews compromises their validity and generalizability, and subsequently their value to key stakeholders. PRISMA-DTA, an extension of the PRISMA statement, was recently developed to improve the quality of reporting of DTA systematic reviews. The PRISMA-DTA statement consists of 27 items, of which 8 are unmodified from the original PRISMA statement. This document provides an explanation for the 19 new and modified items, along with their meaning and rationale. Examples of complete reporting are used for each item to illustrate best practices. The PRISMA-DTA statement, this explanation and elaboration document, and the associated web site (http://www.prisma-statement.org/Extensions/DTA) provide resources to support the complete and transparent reporting of DTA systematic reviews.

AB - Systematic reviews of diagnostic test accuracy (DTA) studies are fundamental to the decision-making process in evidence-based medicine. Although such studies are regarded as high-level evidence, these reviews are not always reported completely and transparently. Sub-optimal reporting of DTA systematic reviews compromises their validity and generalizability, and subsequently their value to key stakeholders. PRISMA-DTA, an extension of the PRISMA statement, was recently developed to improve the quality of reporting of DTA systematic reviews. The PRISMA-DTA statement consists of 27 items, of which 8 are unmodified from the original PRISMA statement. This document provides an explanation for the 19 new and modified items, along with their meaning and rationale. Examples of complete reporting are used for each item to illustrate best practices. The PRISMA-DTA statement, this explanation and elaboration document, and the associated web site (http://www.prisma-statement.org/Extensions/DTA) provide resources to support the complete and transparent reporting of DTA systematic reviews.

U2 - 10.1136/bmj.m2632

DO - 10.1136/bmj.m2632

M3 - Article (Academic Journal)

C2 - 32816740

SN - 0959-8138

VL - 370

JO - BMJ

JF - BMJ

M1 - m2632

ER -

The Preferred Reporting Items for Systematic Review and Meta-Analysis of Diagnostic Test Accuracy studies (PRISMA-DTA): Explanation, Elaboration and Checklist

Abstract

Access to Document

Handle.net

Embargoed Document

Fingerprint

Profiles

Professor Penny F Whiting

Cite this